Dextenza, the first FDA-approved intracanalicular insert for the treatment of postoperative ocular pain, is now also approved for the treatment of ocular inflammation after ophthalmic surgery, Ocular Therapeutix announced in a press release.
The FDA approved a supplemental new drug application for Dextenza (dexamethasone ophthalmic insert 0.4 mg) to include the treatment of ocular inflammation after ophthalmic surgery as an additional indication. Dextenza received FDA approval for postoperative ocular pain in November 2018.
The approval was supported by three phase 3 randomized,
Uncategorized